drugset / Trial / NCT02119221
Copanlisib Mass Balance Study
NaSingle-groupOpen-labelBasic science
Summary
The study aims to provide understanding of the relative relevance of the different excretion pathways of Copanlisib in humans, as well as to characterize its metabolite profile.
Timeline
- Start
- 2014-02
- Primary completion
- 2014-04
- Completion
- 2014-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Copanlisib | Small molecule | 12 mg | Intravenous |
Indications
No indication recorded.